Rockwell Medical, Inc. (RMTI) Announces Earnings Results, Meets Estimates
Rockwell Medical, Inc. (NASDAQ:RMTI) issued its quarterly earnings results on Wednesday. The company reported ($0.10) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.10), Briefing.com reports. The firm had revenue of $14.63 million for the quarter, compared to analyst estimates of $13.33 million. Rockwell Medical had a negative net margin of 39.28% and a negative return on equity of 44.65%. Rockwell Medical’s quarterly revenue was up 14.2% compared to the same quarter last year. During the same period last year, the company posted ($0.09) EPS.
Shares of Rockwell Medical (NASDAQ RMTI) traded up $0.59 during midday trading on Friday, hitting $6.74. 515,313 shares of the stock were exchanged, compared to its average volume of 275,297. Rockwell Medical has a fifty-two week low of $4.90 and a fifty-two week high of $8.98.
ILLEGAL ACTIVITY WARNING: This piece of content was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/rockwell-medical-inc-rmti-announces-earnings-results-meets-estimates/1694373.html.
A number of research analysts recently weighed in on the stock. Zacks Investment Research lowered shares of Rockwell Medical from a “hold” rating to a “sell” rating in a research note on Tuesday, August 15th. BidaskClub raised shares of Rockwell Medical from a “sell” rating to a “hold” rating in a research note on Wednesday, August 23rd. Finally, Ifs Securities assumed coverage on shares of Rockwell Medical in a research note on Monday, August 14th. They issued a “strong-buy” rating and a $11.00 price target on the stock.
About Rockwell Medical
Rockwell Medical, Inc (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process.
Receive News & Ratings for Rockwell Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.